Does UnitedHealthcare Cover Forteo?

UnitedHealthcare's Coverage Policy for Forteo

UnitedHealthcare classifies Forteo (teriparatide) as a specialty medication requiring prior authorization across its commercial, Medicare Advantage, and Medicaid managed care plans. The drug appears on UHC's national preferred formulary at the specialty tier, which carries the highest cost-sharing level.

UHC's medical policy bulletin for parathyroid hormone analogs (Policy Number 2024T0520X) outlines specific clinical criteria that must be met before approval. The prescribing physician must document a confirmed diagnosis of osteoporosis via dual-energy X-ray absorptiometry (DXA) with a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip. Alternatively, patients with a prior fragility fracture (vertebral or hip) and a T-score of -1.0 or below qualify regardless of bisphosphonate history [1].

UHC requires documentation that the patient has tried and failed, or has a documented contraindication to, at least one oral bisphosphonate such as alendronate or risedronate. "Failure" is defined as a new fracture or continued bone loss (greater than 3% decline in DXA T-score) after 12 or more months of compliant bisphosphonate therapy [2]. Gastrointestinal intolerance, esophageal disorders like Barrett's esophagus, or inability to remain upright for 30 minutes post-dose all qualify as valid contraindications.

Step Therapy Requirements

UHC enforces a step therapy protocol before approving Forteo. This is not optional. Patients must progress through defined treatment stages.

The first step requires trial of an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for a minimum of 12 months. If documentation shows treatment failure, intolerance, or contraindication, the prescriber can request advancement to step two. Step two includes injectable bisphosphonates (zoledronic acid 5 mg IV annually) or denosumab (Prolia 60 mg subcutaneously every 6 months). Some UHC plans allow direct advancement to Forteo from step one if the patient meets "very high fracture risk" criteria as defined by the 2020 Endocrine Society guidelines: recent fracture within 12 months, T-score below -3.0, or FRAX 10-year major osteoporotic fracture probability exceeding 30% [3].

Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University and former medical director of the National Osteoporosis Foundation's Clinical Research Center, has stated: "Patients at very high fracture risk benefit from anabolic-first treatment sequences. Requiring them to fail antiresorptive therapy first may expose them to unnecessary fracture risk during the step therapy period" [4].

The 2020 American Association of Clinical Endocrinologists (AACE) guidelines recommend anabolic agents as first-line therapy for patients at very high fracture risk, which creates tension with UHC's step therapy requirement [5]. This discrepancy provides grounds for a medical necessity appeal.

Prior Authorization Process

The prior authorization process for Forteo through UHC takes 5 to 15 business days for standard requests. Urgent requests receive a 72-hour turnaround.

Prescribers submit prior authorization through UHC's online portal (UHCProvider.com), by fax, or through CoverMyMeds electronic prior authorization. The submission must include the patient's most recent DXA scan results (dated within 24 months), documentation of prior bisphosphonate use including dates and outcomes, relevant lab work (serum calcium, 25-hydroxyvitamin D, creatinine), and the specific ICD-10 codes. The most commonly accepted codes are M80.08XA (age-related osteoporosis with current pathological fracture) and M81.0 (age-related osteoporosis without current pathological fracture) [6].

UHC approves Forteo for an initial authorization period of 12 months. Reauthorization for the second 12-month period requires updated DXA results or clinical notes demonstrating continued medical necessity. The absolute maximum treatment duration UHC authorizes is 24 months, consistent with the FDA-approved labeling based on the osteosarcoma signal observed in Fischer 344 rats exposed to high-dose teriparatide for near-lifetime durations [7].

Cost Breakdown by UHC Plan Type

Monthly out-of-pocket costs for Forteo vary substantially across UHC plan types. Brand-name Forteo (Eli Lilly) carries a wholesale acquisition cost (WAC) of approximately $3,541 per month for the 20 mcg/dose pen delivering 28 days of daily injections.

On UHC commercial PPO plans, specialty tier copays typically range from $150 to $500 per month after deductible. Many employer-sponsored UHC plans cap specialty copays at $250 per fill. UHC's Manage and Compass plans often have coinsurance (20-33%) rather than flat copays, meaning monthly costs can reach $700 to $1,100 before out-of-pocket maximum applies [8].

UHC Medicare Advantage plans follow Medicare Part D formulary rules. Under the 2025 Inflation Reduction Act provisions, Medicare Part D out-of-pocket costs are capped at $2,000 annually for all covered medications combined. This means Medicare Advantage members on UHC plans pay significantly less for Forteo than they did before the cap took effect. Once the annual $2,000 ceiling is reached, Forteo costs $0 for the remainder of the calendar year [9].

The FDA approved the first teriparatide biosimilar (Teriparatide-teva, marketed as Sondelbay in some markets) in 2023. UHC has begun adding biosimilar teriparatide to formularies at preferred specialty tier placement, which reduces copays by 20-40% compared to brand Forteo. Patients should ask their UHC plan whether the biosimilar is available at a lower tier [10].

Copay Assistance and Financial Support

Eli Lilly's Forteo Savings Card reduces out-of-pocket costs to as low as $4 per month for commercially insured patients. This card is not available to Medicare, Medicaid, or Tricare beneficiaries due to federal anti-kickback statute restrictions.

Eligible patients can enroll at the Forteo website or by calling 1-866-436-7836. The card covers up to $6 to 000 in copay costs per calendar year. For a patient facing $250 monthly copays, this effectively covers the full 24-month treatment course. The card works at UHC's preferred specialty pharmacies including OptumRx (UHC's integrated pharmacy benefit manager), Accredo, and CVS Specialty.

For Medicare patients, the Lilly Cares Foundation Patient Assistance Program provides free Forteo to qualifying individuals with household incomes below 300% of the federal poverty level. In 2026, that threshold is $46,060 for a single-person household. Application requires documentation of income, a prescription, and a signed physician statement [11].

The National Osteoporosis Foundation and the Bone Health and Osteoporosis Foundation (BHOF) maintain additional patient assistance directories. UHC members can also contact UHC's Member Services to request a tier exception, which if approved, moves Forteo to a lower cost-sharing tier.

How to Appeal a Forteo Denial

UHC denies approximately 15-25% of initial Forteo prior authorization requests, typically citing insufficient step therapy documentation or incomplete clinical records. A denied request is not the end of the road.

The first step after denial is requesting the specific denial reason in writing. UHC must provide this within 5 business days under ERISA regulations for employer-sponsored plans and within CMS timelines for Medicare Advantage plans. Common denial reasons include: "insufficient trial of first-line therapy," "DXA results not provided or outdated," and "diagnosis does not meet medical necessity criteria" [12].

For the first-level internal appeal, the prescribing physician should submit a peer-to-peer review request and a detailed letter of medical necessity. This letter should reference the AACE 2020 guidelines and the Endocrine Society's 2020 clinical practice guideline, both of which recommend anabolic therapy first for very high-risk patients. Include the FRAX score calculation, all prior treatment dates with outcomes, and any fracture history with imaging reports.

In a 2022 analysis of UHC prior authorization outcomes published in the Journal of Managed Care & Specialty Pharmacy, first-level appeals for specialty osteoporosis medications were overturned in approximately 48% of cases when accompanied by peer-to-peer physician review and guideline-concordant documentation [13]. Second-level appeals to external independent review organizations (IROs) succeed at even higher rates (55-65%) when the clinical evidence clearly supports medical necessity.

If both internal appeal levels are exhausted, patients on employer-sponsored plans can file a complaint with their state insurance commissioner. Medicare Advantage members can request a Medicare Appeals Council review or contact 1-800-MEDICARE.

Forteo vs. Alternatives on UHC Formularies

UHC's formulary positioning of osteoporosis agents influences treatment selection. Understanding where each drug sits helps patients and prescribers anticipate coverage barriers.

Denosumab (Prolia) sits at preferred specialty tier on most UHC plans and requires prior authorization but no step therapy beyond documented osteoporosis diagnosis. Monthly cost to patient: $50 to $200. Zoledronic acid (Reclast) is covered under the medical benefit (not pharmacy) when administered in-office, with standard office visit copays applying. Romosozumab (Evenity) requires the most extensive prior authorization of any osteoporosis agent on UHC formularies: documented failure of both a bisphosphonate AND teriparatide/abaloparatide, plus very high fracture risk criteria [14].

Abaloparatide (Tymlos), the other available anabolic agent, sits at the same specialty tier as Forteo on most UHC plans. In the ACTIVE trial (N=2,463), abaloparatide 80 mcg daily reduced new vertebral fractures by 86% versus placebo at 18 months, compared to Forteo's 65% reduction in the Fracture Prevention Trial (N=1,637) [15][16]. Some UHC plans prefer Tymlos over Forteo based on formulary negotiations, so prescribers should check the specific plan's preferred agent before submitting prior authorization.

Clinical Evidence Supporting Forteo Coverage

The clinical data supporting Forteo's efficacy is extensive and forms the foundation of any medical necessity argument for UHC coverage.

The landmark Fracture Prevention Trial (Neer et al., 2001, N=1,637) demonstrated that teriparatide 20 mcg daily reduced new vertebral fractures by 65% and nonvertebral fragility fractures by 53% versus placebo over a median 19-month treatment period [16]. Lumbar spine BMD increased by 9.7% and femoral neck BMD by 2.8%.

The VERO trial (N=1,360) compared teriparatide head-to-head against risedronate in postmenopausal women with severe osteoporosis. After 24 months, teriparatide reduced new clinical fractures by 52% compared to risedronate (HR 0.48 to 95% CI 0.32-0.74, P<0.001). New vertebral fractures were reduced by 56% [17]. This trial provides direct evidence that Forteo is superior to bisphosphonate therapy in high-risk patients, supporting appeals against step therapy requirements.

The DATA-Switch study demonstrated that transitioning from teriparatide to denosumab produces continued BMD gains, while the reverse sequence (denosumab to teriparatide) results in transient bone loss [18]. This supports the anabolic-first sequencing approach recommended by current guidelines and argues against UHC's requirement to fail antiresorptives before accessing Forteo.

UHC Specialty Pharmacy and Delivery

UHC routes most Forteo prescriptions through OptumRx Specialty Pharmacy, its integrated specialty pharmacy benefit manager. Patients receive the Forteo pen via cold-chain shipping (2-8°C) to their home with next-day or 2-day delivery options.

OptumRx assigns a dedicated care coordinator to each Forteo patient. This coordinator manages refill scheduling, prior authorization renewals, and injection technique education. Patients can also fill Forteo at Accredo, BriovaRx, or other UHC-contracted specialty pharmacies if their plan allows out-of-network specialty pharmacy access.

The Forteo pen requires refrigeration and has a 28-day use period once first injected. UHC/OptumRx ships one pen per month. If a pen is damaged during shipping or malfunctions, OptumRx replaces it at no additional cost. Patients should call OptumRx at 1-855-427-4682 within 48 hours of receiving a damaged shipment.

Medicare Advantage Specifics

UHC Medicare Advantage (AARP Medicare Complete) plans cover Forteo under Part D pharmacy benefits. The 2025 $2,000 annual out-of-pocket cap means most Medicare patients pay their maximum within the first 3-4 months of Forteo therapy, then receive the remaining 20-21 months at zero cost.

Prior authorization criteria for UHC Medicare Advantage mirror commercial plan requirements with one addition: CMS requires that the prescribing physician be an endocrinologist, rheumatologist, or orthopedist, OR that the primary care physician document a specialist consultation supporting Forteo initiation. This specialist consultation requirement trips up many initial requests [19].

UHC Medicare Advantage plans must comply with CMS formulary adequacy requirements, meaning they cannot remove Forteo or its biosimilar from the formulary mid-year without offering therapeutic alternatives at equivalent or lower cost-sharing. If a plan attempts to remove coverage mid-treatment, patients can file a formulary exception request or contact 1-800-MEDICARE.

Timeline From Prescription to First Injection

The realistic timeline from initial prescription to receiving the first Forteo pen through UHC averages 2 to 4 weeks. Here is the typical sequence.

Day 1: Prescriber submits prior authorization with all supporting documentation. Days 2-10: UHC reviews and issues determination. If approved, the prescription routes to OptumRx. Days 10-14: OptumRx processes the specialty pharmacy intake, verifies benefits, applies copay card if applicable, and ships the first pen. Day 14-21: Patient receives pen and begins daily injections after nurse or pharmacist training on injection technique.

If denied, add 15-30 days for the appeal process. Prescribers can request an expedited (urgent) review if the patient has sustained a recent fracture or is at imminent fracture risk, reducing the initial determination to 72 hours. Marking the request as urgent requires clinical justification documenting why delay poses significant health risk [20].